No abstract

The disadvantages of highly flexible endoureteral (double J) stents in the face of tumor-induced extrinsic ureteral compression are a consequence of insufficient cross-sectional stability, leading to stent compression and thus to hydronephrosis or pyonephrosis. The newly developed tumor stent, which is used in cases of tumor-induced ureteral compression, is available in sizes from 6F to 8F in diameter and 24 to 32 cm in length. The shaft consists of a combination of high-stability plastics that presents sufficient elasticity in length. Both ends are made of extremely elastic J parts, guaranteeing stable fixation. Compared with common double-J stents with the same outside diameter, the tumor stent possesses a comparable interior diameter and compared with available stents promises sufficient interior flow in the face of extrinsic diseases. The application can be undertaken using well-known endoscopic techniques, needs no special instrumentation, and entails no learning curve. To date, 49 stents were placed at our urologic departments without any problems, the latest stent remaining for 15 months. Tumor-induced compression or a higher rate of encrustation were not seen. All patients tolerated these stents well. In our opinion, the new stabilized endoureteral stent can be seen as a better solution than percutaneous nephrostomy or frequent stent changing to tumor-induced extrinsic ureteral compression.

The disadvantages of high flexible endoureteral stents (DJ) in case of tumorinduced extrinsic ureteral compression are due to an insufficient vertical stability of the used stents leading to stent-compression and consecutive hydro- or pyonephrosis. The new developed tumor-stent used in case of tumor-induced ureteral compression is available from 6 to 8 French in diameter and 24 to 32 cm in length. The corpus consists of a combination of high-stability plastics but is of sufficient elasticity in length. Both ends consist of extremely elastic J-parts guaranteeing an exact fixation. As against common DJ's with the same outside-diameter the new stent has a comparable interior diameter and compared to used "old" tumor stents promises a higher interior flow in case of extrinsic diseases. The application can be undertaken in well-known technique, needs no special instrumentation and no learning-curve. To date 52 stents at our urologic departments were placed without any problems, the latest remaining for 15 months. Tumor-induced compression or a higher rate of encrustation could not be seen. All patients tolerated these stents well. In our opinion the new stabilized endoureteral stent can be seen as a better solution instead of percutaneous nephrostomy or frequent stent changing in patients with tumor induced extrinsic ureteral compression.

No abstract